Coherus restructures, axes 51 staffers in wake of an FDA rejection of its knockoff of Amgen’s Neulasta
Just two weeks after the FDA spurned Coherus’ application to sell a knockoff of Amgen’s Neulasta, the biosimilar maker has come back with a plan …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.